Global Health Limited (MEDANTA) AI Stock Analysis

• Market Cap: ₹279.77B
• Dividend Yield: 0.04%
• Average Volume (3M): 17.50K
• Price to Earnings (P/E): 83.8
• Beta (1Y): 0.64
• Revenue Growth: 15.78%
• EPS Growth: 15.01%
• Country: IN
• Employees: 9,052
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 3.65
• Shares Outstanding: 268,790,370
• 10 Day Avg. Volume: 39,597
• 30 Day Avg. Volume: 17,497
• PEG Ratio: 101.90
• Price to Book (P/B): 9.77
• Price to Sales (P/S): 8.96
• P/FCF Ratio: 308.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,440.00
• Price Target Upside: 18.36% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 20.3
• Revenue Forecast (FY): ₹43.63B

• Rating: 65 Neutral
• Price Target: ₹1,119.00 ▼(-8.03% Downside)
• Action: Downgraded Date: 11/11/25
• Date: Action: Downgraded 11/11/25

Global Health Limited's strong financial performance is a key strength, supported by robust revenue growth and efficient operations. However, technical indicators suggest bearish momentum, and the high P/E ratio indicates potential overvaluation. The lack of earnings call data and corporate events limits further insights.

Positive Factors

Revenue & Margin Expansion

Sustained double-digit top-line growth and stable gross and improving net margins indicate structural demand for higher-acuity services and disciplined cost control. Over 2–6 months this underpins durable earnings power as hospital volumes and case mix drive recurring, higher-margin revenue streams.

Prudent Capital Structure

Low leverage and a high equity ratio provide financial flexibility typical of a capital-intensive hospital operator, lowering refinancing risk and supporting sustained investment in facilities. A healthy ROE shows effective use of capital, reinforcing long-term ability to fund growth and withstand cycles.

Operating Cash Generation

Consistent operating cash that covers net income demonstrates reliable cash conversion from clinical operations, which supports ongoing working capital, service of obligations and targeted capex. This operational cash strength is a durable foundation for reinvestment and stability over months ahead.

Negative Factors

Volatile Free Cash Flow

Material swings in free cash flow reduce predictability of funds available for expansion, dividends or debt paydown. For a hospital network with ongoing capex needs, volatile FCF increases execution risk on growth projects and constrains capital allocation flexibility over the medium term.

Utilization & Case-Mix Sensitivity

Revenue and margins depend heavily on patient volumes, acuity and occupancy. Adverse shifts in utilization, payer behavior, or elective-procedure cycles can materially affect revenue and profitability. This structural sensitivity makes near-term results vulnerable to demand or policy changes.

Limited Forward Guidance

Absent public guidance or substantive earnings-call disclosure reduces visibility into management's view of demand, capacity plans and capital allocation. For investors and counterparties, limited forward signals can increase perceived uncertainty around medium-term performance and strategic priorities.

Global Health Limited Business Overview & Revenue Model

Company Description

Global Health Limited, a multi-specialty tertiary care provider, offers healthcare services in India. The company primarily offers treatments in the areas of cardiology and cardiac science, neurosciences, oncology, digestive and hepatobiliary sciences, orthopedics, liver transplant, and kidney and urology. It operates a network of four hospitals in Gurugram, Indore, Ranchi, and Lucknow under the Medanta brand. Global Health Limited was incorporated in 2004 and is based in Gurgaon, India.

How the Company Makes Money

Medanta primarily makes money by delivering hospital and clinical services to patients and billing for those services. Key revenue streams include: (1) Inpatient services—revenues from room/bed charges, nursing and care services, ICU stays, operation theatre usage, surgical and procedural packages, and other hospitalization-related charges; (2) Outpatient services—consultation fees, clinic-based procedures, follow-up visits, and day-care treatments; (3) Diagnostics and ancillary services—laboratory tests, imaging (e.g., radiology), and other diagnostic procedures performed for inpatients and outpatients; (4) Pharmacy and consumables—sale of medicines, implants, surgical consumables, and other medical supplies used during treatment; and (5) Other hospital-related services—fees linked to specialized therapies and supportive care services offered within the hospital ecosystem. Revenues are typically paid by a mix of self-pay patients and third-party payors such as insurance companies, corporates, and government/TPA-administered health schemes, depending on the patient’s coverage and the applicable reimbursement arrangement. Utilization (patient volumes), case mix (complexity of treatments), occupancy levels, pricing, and the scale of high-acuity specialties (e.g., complex surgeries and critical care) are significant drivers of earnings. Specific named partnerships and exact payer mix details: null.

Global Health Limited Financial Statement Overview

Summary

Global Health Limited exhibits strong financial health with impressive revenue and profit growth, efficient operations, and a stable balance sheet with prudent leverage. While cash flow management is generally positive, fluctuations in free cash flow warrant attention.

Income Statement

Global Health Limited has demonstrated robust revenue growth with a consistent increase over the years, notably a 12.74% increase from 2024 to 2025. The gross profit margin remains strong, reflecting efficient cost management. The net profit margin has improved slightly, indicating enhanced profitability. The company shows strong EBIT and EBITDA margins, suggesting efficient operations and a healthy operating profit.

Balance Sheet

The company maintains a solid balance sheet with a favorable debt-to-equity ratio of 0.21, indicating prudent leverage management. The return on equity (ROE) is strong at 14.21%, showcasing effective use of equity to generate profits. The equity ratio is high at 71.05%, suggesting a stable capital structure with substantial equity financing.

Cash Flow

Global Health Limited has a positive operating cash flow, consistently covering net income, which indicates effective cash management from operations. However, free cash flow growth has been volatile, with a significant decrease in 2025, highlighting potential risks in capital expenditures. The operating cash flow to net income ratio is strong, demonstrating efficient cash generation relative to earnings.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	40.05B	36.92B	32.75B	26.94B	21.67B	14.29B
Gross Profit	28.63B	19.88B	17.17B	20.69B	16.24B	10.81B
EBITDA	10.11B	8.77B	8.72B	6.78B	4.90B	2.23B
Net Income	5.62B	4.81B	4.78B	3.26B	1.96B	288.05M
Balance Sheet
Total Assets	54.10B	47.66B	43.04B	41.16B	31.46B	26.94B
Cash, Cash Equivalents and Short-Term Investments	12.55B	10.51B	11.56B	12.60B	5.12B	2.89B
Total Debt	9.45B	7.18B	8.02B	11.22B	11.09B	9.31B
Total Liabilities	16.99B	13.79B	13.98B	16.88B	15.30B	13.12B
Stockholders Equity	37.08B	33.86B	29.06B	24.28B	16.16B	13.82B
Cash Flow
Free Cash Flow	-841.82M	1.07B	3.33B	4.09B	367.87M	960.32M
Operating Cash Flow	3.29B	6.24B	6.12B	6.45B	3.11B	2.42B
Investing Cash Flow	464.62M	-7.21B	-4.41B	-3.42B	-4.21B	-2.39B
Financing Cash Flow	1.54B	-972.26M	-5.14B	3.46B	1.60B	-807.23M

Global Health Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1216.65
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MEDANTA, the sentiment is Negative. The current price of 1216.65 is above the 20-day moving average (MA) of 1125.19, above the 50-day MA of 1130.19, and below the 200-day MA of 1238.80, indicating a bearish trend. The MACD of -16.73 indicates Positive momentum. The RSI at 32.28 is Neutral, neither overbought nor oversold. The STOCH value of 24.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MEDANTA.

Global Health Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	71 Outperform	₹335.35B	75.82	―	0.24%	14.72%	8.37%
MEDANTA	65 Neutral	₹279.77B	83.79	―	0.04%	15.78%	15.01%
KIMS	65 Neutral	₹258.39B	114.01	―	―	25.74%	1.41%
ASTERDM	62 Neutral	₹336.65B	151.95	―	0.84%	-36.14%	-93.99%
FORTIS	61 Neutral	₹610.50B	86.12	―	0.11%	15.33%	54.62%
METROPOLIS	61 Neutral	₹95.39B	60.35	―	0.21%	15.41%	5.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Global Health Limited Corporate Events

Global Health Publishes Postal Ballot Voting Results and Scrutinizer’s Report

Global Health Limited, the operator of Medanta hospitals, is a listed Indian healthcare services company headquartered in New Delhi and focused on multi-specialty hospital care. It trades on both BSE and NSE under the symbol MEDANTA, serving patients across a range of high-end medical disciplines.

The company has disclosed the results of a recent postal ballot, completed via remote e-voting on March 13, 2026, and has released the scrutinizer’s consolidated report. The voting outcomes and report have been filed with the stock exchanges and made available on both the company’s investor relations website and the NSDL e-voting portal, reinforcing its compliance and transparency obligations to shareholders.

Global Health (Medanta) Receives ESG Rating of 68 for FY2025

Global Health Limited has disclosed that SES ESG Research Private Limited has assigned it an ESG rating of 68 for the financial year 2025. The rating highlights the company’s measured performance on environmental, social and governance parameters and signals to investors and other stakeholders a growing emphasis on formal ESG assessment and transparency in the Indian healthcare sector.